A Novel Therapeutic Strategy for Ehlers-Danlos Syndrome Based on Nutritional Supplements | oneedsvoice

welcome to oneEDSvoice

- a positively charged Ehlers Danlos Syndrome community.
  • join today!
scientific articles

A Novel Therapeutic Strategy for Ehlers-Danlos Syndrome Based on Nutritional Supplements

key information

source: Medical Hypotheses

year: 2005

authors: Mantle D, Wilkins RM, Preedy V

summary/abstract:

Ehlers-Danlos Syndrome is a rare disorder, comprising a group of related inherited disorders of connective tissue, resulting from underlying abnormalities in the synthesis and metabolism of collagen. This proposal is specifically concerned with Ehlers-Danlos syndrome classic type (formerly Types I-III), which is characterized by joint hypermobility and susceptibility to injury/arthritis, skin and vascular problems (including easy bruising, bleeding, varicose veins and poor tissue healing), cardiac mitral valve prolapse, musculo-skeletal problems (myopathy, myalgia, spinal scoliosis, osteoporosis), and susceptibility to periodontitis. No treatment is currently available for this disorder. The novel aspect of this proposal is based on: (i) increasing scientific evidence that nutrition may be a major factor in the pathogenesis of many disorders once thought to result from defective genes alone; (ii) the recognition that many of the symptoms associated with Ehlers-Danlos syndrome are also characteristic of nutritional deficiencies; (iii) the synergistic action within the body of appropriate combinations of nutritional supplements in promoting normal tissue function. We therefore hypothesize that the symptoms associated with Ehlers-Danlos syndrome may be successfully alleviated using a specific (and potentially synergistic) combination of nutritional supplements, comprising calcium, carnitine, coenzyme Q(10), glucosamine, magnesium, methyl sulphonyl methane, pycnogenol, silica, vitamin C, and vitamin K, at dosages which have previously been demonstrated to be effective against the above symptoms in other disorders.

organisation: Pharma Nord

DOI: 10.1016/j.mehy.2004.07.023

read more full text source